These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

568 related articles for article (PubMed ID: 32313940)

  • 1. Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer-a prospective nationwide Swedish multicenter study.
    Marklund A; Eloranta S; Wikander I; Kitlinski ML; Lood M; Nedstrand E; Thurin-Kjellberg A; Zhang P; Bergh J; Rodriguez-Wallberg KA
    Hum Reprod; 2020 Apr; 35(4):929-938. PubMed ID: 32313940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocols.
    Balkenende EME; Dahhan T; Beerendonk CCM; Fleischer K; Stoop D; Bos AME; Lambalk CB; Schats R; Smeenk JMJ; Louwé LA; Cantineau AEP; de Bruin JP; Linn SC; van der Veen F; van Wely M; Goddijn M
    Hum Reprod; 2022 Jul; 37(8):1786-1794. PubMed ID: 35776109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis.
    Arecco L; Blondeaux E; Bruzzone M; Ceppi M; Latocca MM; Marrocco C; Boutros A; Spagnolo F; Razeti MG; Favero D; Spinaci S; Condorelli M; Massarotti C; Goldrat O; Del Mastro L; Demeestere I; Lambertini M
    Hum Reprod; 2022 May; 37(5):954-968. PubMed ID: 35220429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review.
    Rodgers RJ; Reid GD; Koch J; Deans R; Ledger WL; Friedlander M; Gilchrist RB; Walters KA; Abbott JA
    Hum Reprod; 2017 May; 32(5):1033-1045. PubMed ID: 28333356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients.
    Goldrat O; Gervy C; Englert Y; Delbaere A; Demeestere I
    Hum Reprod; 2015 Sep; 30(9):2184-9. PubMed ID: 26109617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is letrozole during ovarian stimulation useful in breast cancer patients undergoing fertility preservation to reduce early luteal progesterone levels following GnRH-agonist trigger?
    Lalami I; Labrosse J; Cedrin-Durnerin I; Comtet M; Vinolas C; Krief F; Sifer C; Peigne M; Grynberg M
    Reprod Biol Endocrinol; 2022 Jun; 20(1):87. PubMed ID: 35690817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing ovarian stimulation for fertility preservation.
    Pereira N; Kelly AG; Stone LD; Witzke JD; Lekovich JP; Elias RT; Schattman GL; Rosenwaks Z
    Fertil Steril; 2017 Sep; 108(3):532-538. PubMed ID: 28865552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IVF characteristics and the molecular luteal features of random start IVF cycles are not different from conventional cycles in cancer patients.
    Esmaeilian Y; Hela F; Bildik G; Akin N; İltumur E; Yusufoglu S; Yildiz CS; Keles İ; Vatansever D; Taskiran C; Yakin K; Oktem O
    Hum Reprod; 2023 Jan; 38(1):113-124. PubMed ID: 36367834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cumulative live birth rates after one ART cycle including all subsequent frozen-thaw cycles in 1050 women: secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols.
    Toftager M; Bogstad J; Løssl K; Prætorius L; Zedeler A; Bryndorf T; Nilas L; Pinborg A
    Hum Reprod; 2017 Mar; 32(3):556-567. PubMed ID: 28130435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of cancer stage and grade on fertility preservation outcome and ovarian stimulation response.
    Volodarsky-Perel A; Cohen Y; Arab S; Son WY; Suarthana E; Dahan MH; Tulandi T; Buckett W
    Hum Reprod; 2019 Mar; 34(3):530-538. PubMed ID: 30689898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled ovarian stimulation outcomes of fertility preservation procedures in newly diagnosed breast cancer patients: a retrospective study from a single-tertiary-IVF centre.
    Sahin G; Goker ENT; Gokmen E; Yeniay L; Acet F; Zekioglu O; Tavmergen E
    J Obstet Gynaecol; 2022 Apr; 42(3):518-523. PubMed ID: 34382483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining fertility preservation procedures to spread the eggs across different baskets: a feasibility study.
    Delattre S; Segers I; Van Moer E; Drakopoulos P; Mateizel I; Enghels L; Tournaye H; De Vos M
    Hum Reprod; 2020 Nov; 35(11):2524-2536. PubMed ID: 32951035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elective and Onco-fertility preservation: factors related to IVF outcomes.
    Cobo A; García-Velasco J; Domingo J; Pellicer A; Remohí J
    Hum Reprod; 2018 Dec; 33(12):2222-2231. PubMed ID: 30383235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer.
    Letourneau JM; Sinha N; Wald K; Harris E; Quinn M; Imbar T; Mok-Lin E; Chien AJ; Rosen M
    Hum Reprod; 2017 Oct; 32(10):2123-2129. PubMed ID: 28938748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders.
    Lainas TG; Sfontouris IA; Venetis CA; Lainas GT; Zorzovilis IZ; Tarlatzis BC; Kolibianakis EM
    Hum Reprod; 2015 Oct; 30(10):2321-30. PubMed ID: 26307091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fertility preservation in female oncology patients: the influence of the type of cancer on ovarian stimulation response.
    Alvarez RM; Ramanathan P
    Hum Reprod; 2018 Nov; 33(11):2051-2059. PubMed ID: 27370358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obstetric and neonatal outcome of ART in patients with polycystic ovary syndrome: IVM of oocytes versus controlled ovarian stimulation.
    Mostinckx L; Segers I; Belva F; Buyl R; Santos-Ribeiro S; Blockeel C; Smitz J; Anckaert E; Tournaye H; De Vos M
    Hum Reprod; 2019 Aug; 34(8):1595-1607. PubMed ID: 31347678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gonadotrophin stimulation and risk of relapse in breast cancer.
    Fredriksson A; Rosenberg E; Einbeigi Z; Bergh C; Strandell A
    Hum Reprod Open; 2021; 2021(1):hoaa061. PubMed ID: 33501382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transgender men's experiences of fertility preservation: a qualitative study.
    Armuand G; Dhejne C; Olofsson JI; Rodriguez-Wallberg KA
    Hum Reprod; 2017 Feb; 32(2):383-390. PubMed ID: 27999119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of breast cancer prognostic factors on oocyte in vitro maturation outcomes performed for urgent fertility preservation.
    Raad J; Sonigo C; Benoit A; Cedrin-Durnerin I; Sifer C; Sermondade N; Grynberg M
    Hum Reprod; 2022 Jun; 37(7):1480-1488. PubMed ID: 35586947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.